Results 121 to 130 of about 93,845 (280)

Posterior ventral tegmental area-nucleus accumbens shell circuitry modulates response to novelty.

open access: yesPLoS ONE, 2019
Dopamine release in the nucleus accumbens from ventral tegmental area (VTA) efferent neurons is critical for orientation and response to novel stimuli in the environment. However, there are considerable differences between neuronal populations of the VTA
Hailong Li   +6 more
doaj   +1 more source

Why Do Makers Make? Examining Designer Motivations on Thingiverse.com [PDF]

open access: yes, 2018
Technological advancements have made a once fictitious dream into a reality. 3D printing has become a popular manufacturing and design technique used all over the world.
Shaw, Courtney H
core   +2 more sources

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

Barnes Hospital Record [PDF]

open access: yes, 1949
https://digitalcommons.wustl.edu/bjc_barnes_record/1028/thumbnail ...

core   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

open access: yesMolecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli   +7 more
wiley   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

open access: yesMolecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

A review of temporal interference, nanoparticles, ultrasound, gene therapy, and designer receptors for Parkinson disease

open access: yesnpj Parkinson's Disease
In this review, we summarize preclinical and clinical trials investigating innovative neuromodulatory approaches for Parkinson disease (PD) motor symptom management.
A. D. Currie, J. K. Wong, M. S. Okun
doaj   +1 more source

Determinação de designer drugs em saliva por paper spray mass spectrometry

open access: yesQuímica Nova
Determination of two drugs of abuse in saliva has been performed by Paper Spray Ionization Mass Spectrometry (PSI-MS) using a Molecularly Imprinted Polymer (MIP) coated paper as substrate.
Lanaia Ítala L. Maciel   +3 more
doaj   +1 more source

Good benefactors managing design expectations [PDF]

open access: yes, 2015
Product design graduates can present themselves as over confident, unrealistic and even arrogant to potential clients. They seem to assume knowledge about their benefactors and have some false expectations of what it means to be a designer.
Thomas, Vicki
core  

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

open access: yesMolecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy